Understanding how ovarian cancer responds to platinum treatment
Official title: Elucidating spatiotemporal dynamics of nascent extracellular matrix in response to platinum treatment in ovarian cancer
Funded at Sanford Research/usd · NIH-11128060 · Data updated 2026-11-12
This study is looking at how the most common type of ovarian cancer responds to platinum-based chemotherapy by exploring changes in the surrounding tissue, and it's designed to help improve treatment for patients who struggle with this tough disease.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sanford Research/usd NIH-funded |
| Lab location | 1 site (Sioux Falls, United States) |
| Project start | May 12, 2025 |
| Project end | April 30, 2030 |
| Funding year | 2025 |
| Award (this year) | $584,081 |
| NIH project number | 1R37CA291976-01A1 |
| Project ID | NIH-11128060 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with high-grade serous ovarian carcinoma who are undergoing or have undergone platinum-based chemotherapy.
✕Less likely to help
Patients with other types of ovarian cancer or those who have not received platinum-based chemotherapy may not benefit from this research.
What this research studies
This research investigates how high-grade serous ovarian carcinoma (HGSC), the most common type of ovarian cancer, reacts to platinum-based chemotherapy by examining the changes in the extracellular matrix (ECM). The study employs advanced technologies to track the dynamics of newly synthesized ECM in response to treatment, using engineered cancer co-cultures and patient-derived tumor samples. By analyzing these changes, the research aims to uncover mechanisms that contribute to chemotherapy resistance, which affects a significant number of patients. The findings could lead to improved treatment strategies for those battling this aggressive cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for ovarian cancer, potentially reducing recurrence rates and improving patient outcomes.
How similar studies have gone: Other research has shown promise in understanding the role of the extracellular matrix in cancer treatment responses, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Sanford Research/usd
Sioux Falls, United States Active
Researchers
- Principal investigator: De la Puente, Pilar — Sanford Research/usd
- Study coordinator: De la Puente, Pilar
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.